Aspire Biopharma Holdings (ASBP) Interest & Investment Income (2022 - 2024)

Aspire Biopharma Holdings (ASBP) has reported Interest & Investment Income for 3 consecutive years, with $169912.0 the latest figure, recorded in Q2 2024.

• On a quarterly basis, Interest & Investment Income fell 91.91% year-over-year to $169912.0 in Q2 2024; TTM through Jun 2024 was $920917.0, a 89.96% decrease from a year earlier, with the FY2024 full-year figure at $548676.0, down 90.56% from the prior year.
• Interest & Investment Income was $169912.0 for Q2 2024 at Aspire Biopharma Holdings, down from $234853.0 in the prior quarter.
• Over five years, Interest & Investment Income peaked at $3.2 million in Q1 2023 and troughed at $21393.0 in Q1 2022.
• A 3-year average of $1.1 million and a median of $339600.5 in 2022 frame the typical range for Interest & Investment Income.
• Across the five-year window, Interest & Investment Income surged 14844.13% in 2023 and slumped 92.65% in 2024, its largest moves.
• Over 3 years, Interest & Investment Income stood at $2.5 million in 2022, then slumped by 89.75% to $260668.0 in 2023, then sank by 34.82% to $169912.0 in 2024.
• The last three Interest & Investment Income figures came in at $169912.0 (Q2 2024), $234853.0 (Q1 2024), and $260668.0 (Q4 2023), per Business Quant data.